Cipla has signed an out-licensing deal with Stempeutics Research, a Biotech firm. The agreement is for stem cell therapy product Stempeucel, indicated for treating critical limb ischemia.
The company will get exclusive marketing rights for five years in India for critical limb ischemia due to atherosclerotic peripheral arterial disease (CLI-PAD) with Stempeutics manufacturing and supplying the product to Cipla.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
